Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Study of Intralesional Injection of RP1 in Patients With Resectable Cutaneous SCC

NCT05858229 is registered in ClinicalTrials.gov with Sherrif Ibrahim as lead sponsor.

NCT NCT05858229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05858229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Study of Intralesional Injection of RP1 in Patients With Resectable Cutaneous SCC
Lead sponsor
Sherrif Ibrahim
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 16, 2023
Completion date
June 30, 2026
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rp1, squamous cell carcinoma